MAVORIC: long-term clinical benefit of mogamulizumab in patients with CTCL

Martine Bagot, MD, PhD, Hôpital Saint Louis, Paris, France, presents results from post hoc analyses of the MAVORIC trial (NCT01728805), a Phase III study evaluating mogamulizumab versus vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). Follow-up studies indicated that long-term responses were not associated with new side effects. In addition, a subset of patients is still in partial or complete response after long-term treatment with mogamulizumab. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.